These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 29108996)

  • 1. FPLD2 LMNA mutation R482W dysregulates iPSC-derived adipocyte function and lipid metabolism.
    Friesen M; Cowan CA
    Biochem Biophys Res Commun; 2018 Jan; 495(1):254-260. PubMed ID: 29108996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The lipodystrophic hotspot lamin A p.R482W mutation deregulates the mesodermal inducer T/Brachyury and early vascular differentiation gene networks.
    Briand N; Guénantin AC; Jeziorowska D; Shah A; Mantecon M; Capel E; Garcia M; Oldenburg A; Paulsen J; Hulot JS; Vigouroux C; Collas P
    Hum Mol Genet; 2018 Apr; 27(8):1447-1459. PubMed ID: 29438482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of LMNA in adipose: a novel mouse model of lipodystrophy based on the Dunnigan-type familial partial lipodystrophy mutation.
    Wojtanik KM; Edgemon K; Viswanadha S; Lindsey B; Haluzik M; Chen W; Poy G; Reitman M; Londos C
    J Lipid Res; 2009 Jun; 50(6):1068-79. PubMed ID: 19201734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Itm2a silencing rescues lamin A mediated inhibition of 3T3-L1 adipocyte differentiation.
    Davies SJ; Ryan J; O'Connor PBF; Kenny E; Morris D; Baranov PV; O'Connor R; McCarthy TV
    Adipocyte; 2017 Oct; 6(4):259-276. PubMed ID: 28872940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of an integration-free induced pluripotent stem cell line (PUMCHi001-A) from a patient with familial partial lipodystrophy type 2 (FPLD2) carrying a heterozygous p.R349W (c.1045C > T) mutation in the LMNA gene.
    Xiao C; Yu M; Liu J; Wu H; Deng M; Zhang Q; Xiao X
    Stem Cell Res; 2020 Jan; 42():101651. PubMed ID: 31794942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered adipocyte differentiation and unbalanced autophagy in type 2 Familial Partial Lipodystrophy: an in vitro and in vivo study of adipose tissue browning.
    Pellegrini C; Columbaro M; Schena E; Prencipe S; Andrenacci D; Iozzo P; Angela Guzzardi M; Capanni C; Mattioli E; Loi M; Araujo-Vilar D; Squarzoni S; Cinti S; Morselli P; Giorgetti A; Zanotti L; Gambineri A; Lattanzi G
    Exp Mol Med; 2019 Aug; 51(8):1-17. PubMed ID: 31375660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adipocyte-Specific Deletion of Lamin A/C Largely Models Human Familial Partial Lipodystrophy Type 2.
    Corsa CAS; Walsh CM; Bagchi DP; Foss Freitas MC; Li Z; Hardij J; Granger K; Mori H; Schill RL; Lewis KT; Maung JN; Azaria RD; Rothberg AE; Oral EA; MacDougald OA
    Diabetes; 2021 Sep; 70(9):1970-1984. PubMed ID: 34088712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipodystrophy-linked LMNA p.R482W mutation induces clinical early atherosclerosis and in vitro endothelial dysfunction.
    Bidault G; Garcia M; Vantyghem MC; Ducluzeau PH; Morichon R; Thiyagarajah K; Moritz S; Capeau J; Vigouroux C; Béréziat V
    Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2162-71. PubMed ID: 23846499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A lipodystrophy-causing lamin A mutant alters conformation and epigenetic regulation of the anti-adipogenic
    Oldenburg A; Briand N; Sørensen AL; Cahyani I; Shah A; Moskaug JØ; Collas P
    J Cell Biol; 2017 Sep; 216(9):2731-2743. PubMed ID: 28751304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypic diversity and glucocorticoid sensitivity in patients with familial partial lipodystrophy type 2.
    Resende ATP; Martins CS; Bueno AC; Moreira AC; Foss-Freitas MC; de Castro M
    Clin Endocrinol (Oxf); 2019 Jul; 91(1):94-103. PubMed ID: 30954027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Site-dependent differences in both prelamin A and adipogenic genes in subcutaneous adipose tissue of patients with type 2 familial partial lipodystrophy.
    Araújo-Vilar D; Lattanzi G; González-Méndez B; Costa-Freitas AT; Prieto D; Columbaro M; Mattioli E; Victoria B; Martínez-Sánchez N; Ramazanova A; Fraga M; Beiras A; Forteza J; Domínguez-Gerpe L; Calvo C; Lado-Abeal J
    J Med Genet; 2009 Jan; 46(1):40-8. PubMed ID: 18805829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deregulation of Fragile X-related protein 1 by the lipodystrophic lamin A p.R482W mutation elicits a myogenic gene expression program in preadipocytes.
    Oldenburg AR; Delbarre E; Thiede B; Vigouroux C; Collas P
    Hum Mol Genet; 2014 Mar; 23(5):1151-62. PubMed ID: 24108105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of an isogenic gene-corrected iPSC line (PUMCHi001-A-1) from a familial partial lipodystrophy type 2 (FPLD2) patient with a heterozygous R349W mutation in the LMNA gene.
    Xiao C; Yu M; Liu J; Wu H; Deng M; Zhang Q; Xiao X
    Stem Cell Res; 2020 Apr; 44():101753. PubMed ID: 32213461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histological and molecular features of lipomatous and nonlipomatous adipose tissue in familial partial lipodystrophy caused by LMNA mutations.
    Araújo-Vilar D; Victoria B; González-Méndez B; Barreiro F; Fernández-Rodríguez B; Cereijo R; Gallego-Escuredo JM; Villarroya F; Pañeda-Menéndez A
    Clin Endocrinol (Oxf); 2012 Jun; 76(6):816-24. PubMed ID: 21883346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Describing the natural history of clinical, biochemical and radiological outcomes of children with familial partial lipodystrophy type 2 (FPLD2) from the United Kingdom: A retrospective case series.
    Zhong ZX; Harris J; Wilber E; Gorman S; Savage DB; O'Rahilly S; Stears A; Williams RM
    Clin Endocrinol (Oxf); 2022 Dec; 97(6):755-762. PubMed ID: 35920656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extracellular matrix remodeling and transforming growth factor-β signaling abnormalities induced by lamin A/C variants that cause lipodystrophy.
    Le Dour C; Wu W; Béréziat V; Capeau J; Vigouroux C; Worman HJ
    J Lipid Res; 2017 Jan; 58(1):151-163. PubMed ID: 27845687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional Body Fat Changes and Metabolic Complications in Children With Dunnigan Lipodystrophy-Causing LMNA Variants.
    Patni N; Li X; Adams-Huet B; Vasandani C; Gomez-Diaz RA; Garg A
    J Clin Endocrinol Metab; 2019 Apr; 104(4):1099-1108. PubMed ID: 30418556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear envelope-related lipodystrophies.
    Guénantin AC; Briand N; Bidault G; Afonso P; Béréziat V; Vatier C; Lascols O; Caron-Debarle M; Capeau J; Vigouroux C
    Semin Cell Dev Biol; 2014 May; 29():148-57. PubMed ID: 24384368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The p.R482W substitution in A-type lamins deregulates SREBP1 activity in Dunnigan-type familial partial lipodystrophy.
    Vadrot N; Duband-Goulet I; Cabet E; Attanda W; Barateau A; Vicart P; Gerbal F; Briand N; Vigouroux C; Oldenburg AR; Lund EG; Collas P; Buendia B
    Hum Mol Genet; 2015 Apr; 24(7):2096-109. PubMed ID: 25524705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polycystic ovary syndrome in familial partial lipodystrophy type 2 (FPLD2): basic and clinical aspects.
    Gambineri A; Zanotti L
    Nucleus; 2018; 9(1):392-397. PubMed ID: 30131000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.